A Phase 3 Study of the Use of PH80 for Acute Management of the Symptoms of Premenstrual Dysphoric Disorder.
Not yet recruiting
Phase of Trial: Phase III
Latest Information Update: 04 Dec 2017
At a glance
- Drugs PH 80 (Primary)
- Indications Premenstrual dysphoric disorder
- Focus Therapeutic Use
- Sponsors Pherin Pharmaceuticals
- 02 Dec 2015 Planned End Date changed from 1 Oct 2013 to 1 Jul 2017, as reported by ClinicalTrials.gov.
- 02 Dec 2015 Planned initiation date changed from 1 May 2011 to 1 Mar 2016, as reported by ClinicalTrials.gov.
- 15 Oct 2010 New trial record